Menu

Blog

Archive for the ‘life extension’ category: Page 216

Dec 12, 2020

​​Ushering in an ageless future

Posted by in categories: life extension, robotics/AI, singularity

For years, futurists have attempted to predict when, in the future, we will finally achieve the technological singularity’’ — a technological breakthrough so profound, it changes the course of humanity. Specifically, futurists have been talking about the moment when super-human artificial intelligence becomes reality. Or — to put it simply — when computers become smarter than people.

However, at Centaura, we believe that the world needs to prepare for a different singularity — one that might arrive even before super-human intelligence. It’s the moment when humans have the power to slow down — and even reverse aging.

The idea of the singularity first became popular nearly thirty years ago by the science fiction writer Vernor Vinge. In his essay The Coming Technological Singularity, he famously declared, Within thirty years, we will have the technological means to create superhuman intelligence. Shortly after, the human era will be ended.

Dec 12, 2020

Yuri Deigin — Defeating Aging

Posted by in categories: biotech/medical, business, cryonics, genetics, life extension, neuroscience

Andres de Tenyi.


Yuri Deigin, MBA is a serial biotech entrepreneur, longevity research evangelist and activist, and a cryonics advocate. He is an expert in drug development and venture investments in biotechnology and pharmaceuticals. He is the CEO at Youthereum Genetics and the Vice President at Science for Life Extension Research Support Foundation.
http://youthereum.ca/

Continue reading “Yuri Deigin — Defeating Aging” »

Dec 12, 2020

Stephen Langevin

Posted by in categories: biotech/medical, cyborgs, education, life extension, robotics/AI, transhumanism

I just read an incredible post about Transhumanism by Francesco Neo Amati, CM of Transhumanism: The Future of Humanity.

What an excellent representation of how pragmatic and collaborative our community can be. People like Francesco Neo Amati are the reason why I call myself a Transhumanist…

“Community Announcement:

Continue reading “Stephen Langevin” »

Dec 12, 2020

Genetic engineering transformed stem cells into working mini-livers that extended the life of mice with liver disease

Posted by in categories: bioengineering, biotech/medical, chemistry, computing, food, genetics, life extension, neuroscience

Takeaways * Scientists have made progress growing human liver in the lab. * The challenge has been to direct stems cells to grow into a mature, functioning adult organ. * This study shows that stem cells can be programmed, using genetic engineering, to grow from immature cells into mature tissue. * When a tiny lab-grown liver was transplanted into mice with liver disease, it extended the lives of the sick animals.* * *Imagine if researchers could program stem cells, which have the potential to grow into all cell types in the body, so that they could generate an entire human organ. This would allow scientists to manufacture tissues for testing drugs and reduce the demand for transplant organs by having new ones grown directly from a patient’s cells. I’m a researcher working in this new field – called synthetic biology – focused on creating new biological parts and redesigning existing biological systems. In a new paper, my colleagues and I showed progress in one of the key challenges with lab-grown organs – figuring out the genes necessary to produce the variety of mature cells needed to construct a functioning liver. Induced pluripotent stem cells, a subgroup of stem cells, are capable of producing cells that can build entire organs in the human body. But they can do this job only if they receive the right quantity of growth signals at the right time from their environment. If this happens, they eventually give rise to different cell types that can assemble and mature in the form of human organs and tissues. The tissues researchers generate from pluripotent stem cells can provide a unique source for personalized medicine from transplantation to novel drug discovery. But unfortunately, synthetic tissues from stem cells are not always suitable for transplant or drug testing because they contain unwanted cells from other tissues, or lack the tissue maturity and a complete network of blood vessels necessary for bringing oxygen and nutrients needed to nurture an organ. That is why having a framework to assess whether these lab-grown cells and tissues are doing their job, and how to make them more like human organs, is critical. Inspired by this challenge, I was determined to establish a synthetic biology method to read and write, or program, tissue development. I am trying to do this using the genetic language of stem cells, similar to what is used by nature to form human organs. Tissues and organs made by genetic designsI am a researcher specializing in synthetic biology and biological engineering at the Pittsburgh Liver Research Center and McGowan Institute for Regenerative Medicine, where the goals are to use engineering approaches to analyze and build novel biological systems and solve human health problems. My lab combines synthetic biology and regenerative medicine in a new field that strives to replace, regrow or repair diseased organs or tissues. I chose to focus on growing new human livers because this organ is vital for controlling most levels of chemicals – like proteins or sugar – in the blood. The liver also breaks down harmful chemicals and metabolizes many drugs in our body. But the liver tissue is also vulnerable and can be damaged and destroyed by many diseases, such as hepatitis or fatty liver disease. There is a shortage of donor organs, which limits liver transplantation. To make synthetic organs and tissues, scientists need to be able to control stem cells so that they can form into different types of cells, such as liver cells and blood vessel cells. The goal is to mature these stem cells into miniorgans, or organoids, containing blood vessels and the correct adult cell types that would be found in a natural organ. One way to orchestrate maturation of synthetic tissues is to determine the list of genes needed to induce a group of stem cells to grow, mature and evolve into a complete and functioning organ. To derive this list I worked with Patrick Cahan and Samira Kiani to first use computational analysis to identify genes involved in transforming a group of stem cells into a mature functioning liver. Then our team led by two of my students – Jeremy Velazquez and Ryan LeGraw – used genetic engineering to alter specific genes we had identified and used them to help build and mature human liver tissues from stem cells. The tissue is grown from a layer of genetically engineered stem cells in a petri dish. The function of genetic programs together with nutrients is to orchestrate formation of liver organoids over the course of 15 to 17 days. Liver in a dishI and my colleagues first compared the active genes in fetal liver organoids we had grown in the lab with those in adult human livers using a computational analysis to get a list of genes needed for driving fetal liver organoids to mature into adult organs. We then used genetic engineering to tweak genes – and the resulting proteins – that the stem cells needed to mature further toward an adult liver. In the course of about 17 days we generated tiny – several millimeters in width – but more mature liver tissues with a range of cells typically found in livers in the third trimester of human pregnancies. Like a mature human liver, these synthetic livers were able to store, synthesize and metabolize nutrients. Though our lab-grown livers were small, we are hopeful that we can scale them up in the future. While they share many similar features with adult livers, they aren’t perfect and our team still has work to do. For example, we still need to improve the capacity of the liver tissue to metabolize a variety of drugs. We also need to make it safer and more efficacious for eventual application in humans.[Deep knowledge, daily. Sign up for The Conversation’s newsletter.]Our study demonstrates the ability of these lab livers to mature and develop a functional network of blood vessels in just two and a half weeks. We believe this approach can pave the path for the manufacture of other organs with vasculature via genetic programming. The liver organoids provide several key features of an adult human liver such as production of key blood proteins and regulation of bile – a chemical important for digestion of food. When we implanted the lab-grown liver tissues into mice suffering from liver disease, it increased the life span. We named our organoids “designer organoids,” as they are generated via a genetic design. This article is republished from The Conversation, a nonprofit news site dedicated to sharing ideas from academic experts. It was written by: Mo Ebrahimkhani, University of Pittsburgh. Read more: * Brain organoids help neuroscientists understand brain development, but aren’t perfect matches for real brains * Why are scientists trying to manufacture organs in space?Mo Ebrahimkhani receives funding from National Institute of Health, University of Pittsburgh and Arizona Biomedical Research Council.

Dec 12, 2020

Breakthrough NASA Study Discovers Surprising Key to Astronauts’ Health in Space

Posted by in categories: biotech/medical, life extension

This month, a collaboration between NASA and various research institutions pinpointed a “central biological hub” that controls health during space travel. The culprit is the cell’s energy factory, the mitochondria, which breaks down in function in a way eerily similar to aging. Like shutting down power and water in a city, disruptions to the mitochondria reverberate throughout the cells and organs, potentially leading to problems with sleeping, the immune system, and more in space. The results were [published in *Cell](https://www.cell.com/cell/fulltext/S0092-8674(20)31461-6).*

Dec 12, 2020

Dr. James Weinstein, SVP Microsoft — Creating Healthcare With Value, Outcomes & Equity For Patients

Posted by in categories: biotech/medical, business, engineering, life extension, policy

Microsoft Health-Tech Vision


Dr. James Weinstein, is Senior Vice President, Microsoft Healthcare, where he is in charge of leading strategy, innovation and health equity functions.

Continue reading “Dr. James Weinstein, SVP Microsoft — Creating Healthcare With Value, Outcomes & Equity For Patients” »

Dec 12, 2020

Why We Should Exercise Regularly — Ten Amazing Benefits

Posted by in categories: biotech/medical, life extension, neuroscience

If you want to live long enough to see a reversal of aging and everlasting youth, exercise should be at the core of your routine.

Here I look at ten amazing benefits that exercise brings to your body and mind, so if you haven’t already got a regime on the go, hopefully this will convince you to start now.

Continue reading “Why We Should Exercise Regularly — Ten Amazing Benefits” »

Dec 11, 2020

Reversing Senescence Through The Skin — Dr. Carolina Reis, CEO & Co-Founder, OneSkin Technologies

Posted by in categories: biotech/medical, chemistry, food, information science, life extension

Dr. Carolina Reis Oliveria, is the CEO and Co-Founder of OneSkin Technologies, a biotechnology platform dedicated to exploring longevity science.

Carolina holds her Ph.D. in Immunology at the Federal University of Minas Gerais, in collaboration with the Rutgers University, where she conducted research with pluripotent stem cells as a source of retinal pigmented epithelium (RPE) cells, as well as the potential of RPE-stem cells derived as toxicological models for screening of new drugs with intra-ocular applications.

Continue reading “Reversing Senescence Through The Skin — Dr. Carolina Reis, CEO & Co-Founder, OneSkin Technologies” »

Dec 11, 2020

Send in the senolytics

Posted by in category: life extension

Despite early failures in the clinic, the idea of anti-aging therapies that purge the body of dying cells is gaining traction with a raft of startups now focused on senescence.

Dec 10, 2020

Brain-on-a-chip: A history of development and future perspective

Posted by in categories: biotech/medical, life extension, neuroscience

Brain on a chip for drug discovery.


Since the advent of organ-on-a-chip, many researchers have tried to mimic the physiology of human tissue on an engineered platform. In the case of brain tissue, structural connections and cell–cell interactions are important factors for brain function. The recent development of brain-on-a-chip is an effort to mimic those structural and functional aspects of brain tissue within a miniaturized engineered platform. From this perspective, we provide an overview of trace of brain-on-a-chip development, especially in terms of complexity and high-content/high-throughput screening capabilities, and future perspectives on more in vivo-like brain-on-a-chip development.

With the advent of an aging society, the disease incidence rate is increasing, and the cost of drug development and disease treatment is expanding exponentially.1,2 According to the World Health Organization (WHO), nearly one billion people in the world suffer from neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s diseases.3 Despite decades of research on neurodegenerative diseases by many biologists and pharmaceutical companies, the underlying mechanism of their onset and progression is still largely unknown. The resolution of these diseases has a long way to go, and such steps are limited due to the lack of a suitable in vitro model system for mechanism study and drug development. In particular, the complex tissue structures and cell–cell interactions of the in vivo system make it challenging to unravel the underlying mechanism of the diseases and to predict the efficacy of clinical medicine.